TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

Eligible age

18–75 yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.

Sponsor: Altimmune, Inc.

You may qualify if…

  • ✓ All subjects:
  • ✓ No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
  • ✓ Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
  • ✓ Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
  • ✓ Subject agrees to have liver biopsy(ies) as required per protocol
  • ✓ Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
  • ✓ Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing

You may not qualify if…

  • ✕ Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
  • ✕ Uncontrolled T2D or clinically significant persistent hyperglycemia

Where it's recruiting

Alabama

Dothan

Arizona

Chandler · Tucson

Arkansas

Little Rock · North Little Rock

California

Fountain Valley · Fresno · Gardena · Huntington Park …

Colorado

Englewood

Florida

Boca Raton · Bradenton · Miami · Miami Lakes …

Georgia

Dalton

Indiana

South Bend

Louisiana

Bastrop · Marrero · Monroe

Maryland

Laurel

Massachusetts

New Bedford

Missouri

Columbia · Kansas City

Source: ClinicalTrials.gov · NCT07795164 · last updated 2026-11-17

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvid · TrialPath